Pharmacokinetic study and cardiovascular monitoring of nebivolol in normal and obese subjects

European Journal of Clinical Pharmacology

Volumn 51, Issue 6, 1997, Pages 493-498

  Cheymol, G ^a   Woestenborghs, R ^b   Snoeck, E ^b   Ianucci, R ^a   Le Moing, J P ^b   Naditch, L ^a   Levron, J C ^b   Poirier, J M ^a  

^a HÔPITAL SAINT ANTOINE   (France)

^b Janssen Research Foundation   (France)

Author keywords

Cardiovascular effects; Healthy volunteers; Nebivolol; Obese subjects; Pharmacokinetics

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DRUG METABOLITE; NEBIVOLOL;

ADIPOSE TISSUE; ADULT; ARTICLE; BODY WEIGHT; CARDIOVASCULAR EFFECT; CONTROLLED STUDY; DISTRIBUTION VOLUME; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG TISSUE LEVEL; ENANTIOMER; FEMALE; HEART OUTPUT; HEART RATE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; HUMAN TISSUE; HYDROXYLATION; LIPOPHILICITY; MALE; NORMAL HUMAN; OBESITY; PHENOTYPE; PRIORITY JOURNAL; RACEMIC MIXTURE; RADIOIMMUNOASSAY; STEADY STATE;

ADRENERGIC BETA-ANTAGONISTS; ADULT; BENZOPYRANS; BLOOD PRESSURE; CARDIAC OUTPUT; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; ETHANOLAMINES; FEMALE; HALF-LIFE; HEART RATE; HUMANS; LIPIDS; MALE; OBESITY;

EID: 0030757923     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280050237     Document Type: Article

References (20)

1. Cheymol G (1993) Clinical pharmacokinetics of drug in obesity: an update. Clin Pharmacokinet 25: 103-114
2. Abernethy DR (1986) Drug disposition in obese humans. An update. Clin Pharmacokinet 11: 199-213
3. Cheymol G, Poirier JM, Barre J, Pradalier A, Dry J (1987) Comparative pharmacokinetics of intravenous propranolol in obese and normal volunteers. J Clin Pharmacol 27: 874-879
4. Le Jeune C, Poirier JM, Cheymol G, Ertzbischoff O, Engel F, Hugues FC (1991) Pharmacokinetics of i.v. bisoprolol in obese and non-obese volunteers. Eur J Clin Pharmacol 41: 171-174.
5. Janssens WJ, Xhonneux R, Janssen PAJ (1991) Animal pharmacology of nebivolol. Drug Investig 3 (Suppl 1): 13-24
6. Van Peer A, Snoeck E, Woestenborghs R, Van de Velde V, Mannens G, Meuldermans W, Heykants J (1991) Clinical pharmacokinetics of nebivolol. A review. Drug Investig 3 (Suppl 1): 25-30
7. Anonymous (1989) Weights of insured persons in the United States associated with lowest mortality. Stat Bull Metrop Insur Co 40, November-December
8. Hinderliter AL, Eitzpatrick MA, Shork N, Julius S (1987) Research utility of non-invasive methods for measurement of cardiac output. Clin Pharmacol Ther 41: 419-425
9. Woestenborghs R, Geuens I, Lenoir H, Janssen C, Heykants J (1990) On the selectivity of some recently developed RIA's. In Reid E, Wilson ID (eds) Methodological surveys in biochemistry and analysis. Royal Society of Chemistry 20: 241-246
10. 1-adrenoceptor blocking agent nebivolol in human plasma. In Reid E et al (eds) Methodological surveys in biochemistry and analysis, vol 18. Plenum Press, New York pp 215-216.
11. Hidelbrand M, Seifert W, Reichenberger A (1989) Determination of dextromethorphan metabolizer phenotype in healthy volunteers. Eur J Clin Pharmacol 36: 315-318
12. Gomeni R (1984) Pharm: an interactive graphic program for individual and population pharmacokinetic parameter population. Comp Biol Med 14: 25-34
13. McLay JS, Irvine N, McDevitt DG (1991) Clinical pharmacology of nebivolol. Drug Investig 3 (Suppl 1): 31-32
14. Van Rooy P, Van Nueten L, De Cree J (1991) Blood pressure reduction in relation to β-blockade in healthy volunteers. Drug Investig 3 (Suppl 1): 174-175
15. Van Rooy P, De Cree J (1991) Haemodynamic effects of nebivolol in poor and extensive metabolisers. Drug Investig 3 (Suppl 1): 161-163
16. Bickel MH (1993) Lipophilicity and drugs distribution into adipose tissues. Proceedings of the international symposium on blood binding and drug transfer. Editions Fort et Clair, Paris, pp 147-156
17. Bentley JB, Vaughan RW, Gandolfi AJ, Cork RC (1981) Altered halothane metabolism: obese vs. non-obese subjects. Anesthesiology 55A: 179
18. Milsap RL, Plaisance KI, Jusko WJ (1984) Prednisolone disposition in obese men. Clin Pharmacol Thor 36: 824-831
19. O'Shea D, Davis SN, Kim RB, Wilkinson GR (1994) Effect of fasting and obesity in humans on the 6-hydroxylation of chlorzoxazone: a putative probe of CYP2E1 activity. Clin Pharmacol Ther 56: 359-367
20. Braillon A, Capron JP, Herve MA, Degott G, Quenum C (1985) Liver in obesity. Gut 26: 133-139